Firma Mikrogen, Autor bei Presse-Blog

MIKROGEN Acquires Lophius Biosciences To Expand Into T Cell-Based Testing Market

8. März 20212. Mai 2024 Firma MikrogenBiotechnik'cmv', acquisition, automation, biopark, blood-based, cell-mediated immunity, development program, diagnostic, ivd, Lophius Biosciences, mikrogen, neuried, regensburg, T-cell, tuberculosis

Mikrogen GmbH today announced that it has acquired the assets & technologies of Lophius Biosciences GmbH. Combining Mikrogen’s expertise in diagnostics and automation with Lophius’ technology for pathogen-specific immune stimulation will enable novel diagnostic solutions for infectious diseases and complement Mehr

Lophius Biosciences Closes Financing Round To Set New Standard In Tuberculosis Diagnosis

19. September 201917. März 2022 Firma MikrogenBiotechnikbiomarker, blood-based, clinical validation, diagnostic, financing round, funds, healthcare, igra, infection detection, Lophius Biosciences, ltbi, patient management, pcr, tuberculosis

Lophius Biosciences GmbH today announced that the company has closed a financing round of €3.1m led by VRD GmbH, supported by the Bavarian Growth Fund (“Wachstumsfonds Bayern”) of Bayern Kapital GmbH and private investors. The company will use the funds Mehr

Lophius Biosciences Achieves Development Milestone in Establishing High-Performance Tuberculosis Infection Detection Test

7. Mai 201917. März 2022 Firma MikrogenBiotechnikautomation platforms, clinical validation, diagnostics, healthcare, igra, infection detection, Lophius Biosciences, ltbi, milestone, patient management, pcr, performance, treatment paradigms, tuberculosis

Lophius Biosciences GmbH today announced that the company has achieved an important development milestone for its proprietary, blood-based, multi-marker tuberculosis (TB) infection detection assay. During a clinical study, Lophius’ novel test system outperformed predefined performance goals for detecting the presence Mehr

Positive T-Track® CMV Study Results With New Guidance Strategies For Anti-viral Treatment Decisions Following Stem Cell Transplantation

7. Februar 201917. März 2022 Firma MikrogenBiotechnik'cmv', clinical, CMV-CMI, ELISpot, HSCT, immunology, in-vitro diagnostics, kidney, Lophius Biosciences, patient management, transplant, treatment, treatment paradigms, tuberculosis

Lophius Biosciences GmbH today announced successful top-line results from its multicenter AlloProtect CMV clinical study. Results show the ability of Lophius’ CE-marked in vitro diagnostic test T-Track® CMV to transform treatment paradigms and patient management: in patients receiving an allogeneic Mehr

T-Track® CMV is a Highly Sensitive Immune-Monitoring Tool for Risk Stratification of Renal Transplant Recipients

8. Februar 201817. März 2022 Firma MikrogenBiotechnik'cmv', biotechnology, bone marrow transplantation, cell-mediated immunity, CMV-CMI, CMV-specific, cytomegalovirus, ELISpot, immunology, in-vitro diagnostic, Lophius Biosciences, publications, regensburg, scientific, solid organ transplantation, Transplantation

Lophius Biosciences GmbH today announced the publication of a peer-reviewed scientific paper covering the company’s CE-marked in vitro diagnostic test T-Track® CMV in a clinical study with kidney transplant patients. The scientific publication outlines that T-Track® CMV is a highly Mehr

Lophius and Mediphos sign exclusive distribution partnership for T-Track® CMV in the Benelux countries

27. September 201717. März 2022 Firma MikrogenBiotechnik'cmv', Belgium, biopark, biotechnology, cell-mediated immunity, CMV-CMI, cytomegalovirus, Distribution, ELISpot, immunology, in-vitro diagnostic, ivd, Lophius Biosciences, luxemburg, Mediphos Medical Supplies, Netherlands, regensburg, T-activation, T-cell, Transplantation

Lophius Biosciences GmbH and Mediphos Medical Supplies B.V. today announced their distribution partnership for the in vitro diagnostic test T-Track® CMV. Under the recently-signed collaboration agreement, Mediphos will exclusively market and sell Lophius’ novel immune-monitoring tool in The Netherlands, Belgium Mehr

Launch of the Next Generation T-Track® CMV Immune Monitoring Tool

1. September 201717. März 2022 Firma MikrogenBiotechnik'cmv', biopark, Biotech, biotechnology, cell-mediated immunity, CMV-CMI, cytomegalovirus, ELISpot, immunology, in-vitro diagnostic, Lophius Biosciences, regensburg, T-activation, T-cell, Transplantation

Lophius Biosciences GmbH today announced the launch of the next generation of its in vitro diagnostic test T-Track® CMV for the risk stratification of human cytomegalovirus (CMV)-related clinical complications in transplant recipients. The new version of the CE-marked immune monitoring Mehr

Autor: Firma Mikrogen